{"id":639244,"date":"2023-02-20T20:14:01","date_gmt":"2023-02-20T20:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=639244"},"modified":"2023-02-20T20:14:01","modified_gmt":"2023-02-20T20:14:01","slug":"dry-eye-disease-pipeline-drugs-and-companies-insight-report-2023-updates-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/dry-eye-disease-pipeline-drugs-and-companies-insight-report-2023-updates-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_639244.html","title":{"rendered":"Dry Eye Disease Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1676895636.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Dry Eye Disease Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" src=\"https:\/\/www.abnewswire.com\/uploads\/1676895636.jpeg\" alt=\"Dry Eye Disease Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Las Vega (Nevada), United States \/\/\u2014 As per DelveInsight\u2019s assessment, globally, Dry Eye Disease pipeline constitutes key companies continuously working towards developing Dry Eye Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.<\/div>\n<p style=\"text-align: justify;\"><strong>Dry Eye Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Dry eye disease (DED), also known as dry eye syndrome (DES), keratoconjunctivitis sicca (KCS), and keratitis sicca, is a multifactorial disease of the ocular surface due to a loss of homeostasis of the tear film. It often results in ocular symptoms and visual disturbance due to underlying tear film instability, ocular suface inflammation and damage, and neurosensory abnormalities.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dry-eye-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Dry Eye Disease Pipeline Insight, 2023<\/a>&#8220;<\/strong> report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dry Eye Disease Market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Dry Eye Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key takeaways from the Dry Eye Disease Pipeline Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Companies across the globe are diligently working toward developing novel Dry Eye Disease treatment therapies with a considerable amount of success over the years. Dry Eye Disease Key players such as &#8211; <strong>Quorum Innovations, Serentrix, Cellix Bio, Taejoon Pharmaceutical Co., Ltd., Seinda Pharmaceutical, Invirsa, GL Pharm Tech Corporation, Dreamhawk Vision Biotech, Inc., Aramis Biosciences, Kowa Research Institute, Inc., Aerie Pharmaceuticals, HanAll Biopharma, Seikagaku Corporation, Novaliq GmbH,<\/strong> and others, are developing therapies for the Dry Eye Disease treatment&nbsp;<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Dry Eye Disease Emerging therapies such as &#8211; <strong>Qi 401, SER-114, CLX-OPH-621, TJO-083, SY-201, INV-102, GLH8NDE,SHJ 002, A197, K-161, AR-15512, HL036, SI-614, NOV03, CyclASol<\/strong>, and others are expected to have a significant impact on the Dry Eye Disease market in the coming years.&nbsp;&nbsp;&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\">Dry Eye Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Intra-articular<\/li>\n<li>Intraocular<\/li>\n<li>Intrathecal&nbsp;<\/li>\n<li>Intravenous<\/li>\n<li>Ophthalmic<\/li>\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical<\/li>\n<li>Transdermal<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\">Products have been categorized under various Molecule types, such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>Oligonucleotide<\/li>\n<li>Peptide<\/li>\n<li>Small molecule<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dry Eye Disease Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Dry Eye Disease Assessment by Product Type<\/li>\n<li>Dry Eye Disease By Stage and Product Type<\/li>\n<li>Dry Eye Disease Assessment by Route of Administration<\/li>\n<li>Dry Eye Disease By Stage and Route of Administration<\/li>\n<li>Dry Eye Disease Assessment by Molecule Type<\/li>\n<li>Dry Eye Disease by Stage and Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&#8217;s Dry Eye Disease Report covers around products under different phases of clinical development like-<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I)<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key companies in the Dry Eye Disease Therapeutics Market include:<\/strong><\/p>\n<p style=\"text-align: justify;\">Key companies developing therapies for Dry Eye Disease treatment are &#8211;<strong><em> AbbVie Inc. (Allergan PLC), AFT Pharmaceuticals, Akorn, Alcon Inc., Bausch Health Companies Inc., Horus Pharma, Johnson &amp; Johnson, Mitotech, Novaliq GmbH, OASIS Medical, Otsuka Pharmaceutical Co. Ltd, Prestige Consumer Healthcare, Santen Pharmaceutical Co. Ltd, Sentiss Pharma Pvt. Ltd, Sun Pharmaceutical Industries Ltd, and VISUfarma,<\/em><\/strong> and others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Emerging Dry Eye Disease Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Qi 401:<\/strong> Quorum Innovations<\/li>\n<li><strong>SER-114:<\/strong> Serentrix<\/li>\n<li><strong>CLX-OPH-621:<\/strong> Cellix Bio<\/li>\n<li><strong>TJO-083:<\/strong> Taejoon Pharmaceutical Co., Ltd.<\/li>\n<li><strong>SY-201:<\/strong> Seinda Pharmaceutical<\/li>\n<li><strong>INV-102:<\/strong> Invirsa<\/li>\n<li><strong>GLH8NDE:<\/strong> GL Pharm Tech Corporation<\/li>\n<li><strong>SHJ 002:<\/strong> Dreamhawk Vision Biotech, Inc.<\/li>\n<li><strong>A197:<\/strong> Aramis Biosciences<\/li>\n<li><strong>K-161:<\/strong> Kowa Research Institute, Inc.<\/li>\n<li><strong>AR-15512:<\/strong> Aerie Pharmaceuticals<\/li>\n<li><strong>HL036:<\/strong> HanAll Biopharma &nbsp; &nbsp; &nbsp; &nbsp;<\/li>\n<li><strong>SI-614:<\/strong> Seikagaku Corporation<\/li>\n<li><strong>NOV03:<\/strong> NovaliqGmbH<\/li>\n<li><strong>CyclASol:<\/strong> NovaliqGmbH<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free Sample PDF Report to know more about Dry Eye Disease Pipeline Therapeutic Assessment- <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dry-eye-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/sample-request\/dry-eye-disease-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dry Eye Disease Pipeline Analysis:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Dry Eye Disease pipeline report provides insights into&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Dry Eye Disease with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dry Eye Disease Treatment.<\/li>\n<li>Dry Eye Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Dry Eye Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dry Eye Disease market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Further Dry Eye Disease product details are provided in the report. Download the Dry Eye Disease pipeline report to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dry-eye-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">emerging Dry Eye Disease therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dry Eye Disease Pipeline Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Rise in geriatric population<\/li>\n<li>Increasing Exposure to computer screens<\/li>\n<li>Increased R&amp;D Activities<\/li>\n<li>Adoption of new Technologies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dry Eye Disease Pipeline Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Lack of awareness about dry eye disease in low income countries<\/li>\n<li>Complexity of the disease<\/li>\n<li>Challenges associated with the Ocular drug delivery<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of Dry Eye Disease Pipeline Drug Insight&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage: Global<\/strong><\/li>\n<li><strong>Key Dry Eye Disease Companies:<\/strong> Quorum Innovations, Serentrix, Cellix Bio, Taejoon Pharmaceutical Co., Ltd., Seinda Pharmaceutical, Invirsa, GL Pharm Tech Corporation, Dreamhawk Vision Biotech, Inc., Aramis Biosciences, Kowa Research Institute, Inc., Aerie Pharmaceuticals, HanAll Biopharma, Seikagaku Corporation, NovaliqGmbH, and others<\/li>\n<li><strong>Key Dry Eye Disease Therapies:<\/strong> Qi 401, SER-114, CLX-OPH-621, TJO-083, SY-201, INV-102, GLH8NDE,SHJ 002, A197, K-161, AR-15512, HL036, SI-614, NOV03, CyclASol, and others<\/li>\n<li><strong>Dry Eye Disease Therapeutic Assessment:<\/strong> Dry Eye Disease current marketed and Dry Eye Disease emerging therapies<\/li>\n<li><strong>Dry Eye Disease Market Dynamics: Dry Eye Disease market drivers and Dry Eye Disease market barriers&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report for <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dry-eye-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Dry Eye Disease Pipeline Assessment and clinical trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<table border=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>\n<p>1<\/p>\n<\/td>\n<td>\n<p>Dry Eye Disease Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>2<\/p>\n<\/td>\n<td>\n<p>Dry Eye Disease Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>3<\/p>\n<\/td>\n<td>\n<p>Dry Eye Disease Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>4<\/p>\n<\/td>\n<td>\n<p>Dry Eye Disease- Analytical Perspective In-depth Commercial Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>5<\/p>\n<\/td>\n<td>\n<p>Dry Eye Disease Pipeline Therapeutics<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>6<\/p>\n<\/td>\n<td>\n<p>Dry Eye Disease Late Stage Products (Phase II\/III)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>7<\/p>\n<\/td>\n<td>\n<p>Dry Eye Disease Mid Stage Products (Phase II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>8<\/p>\n<\/td>\n<td>\n<p>Dry Eye Disease Early Stage Products (Phase I)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>9<\/p>\n<\/td>\n<td>\n<p>Dry Eye Disease Preclinical Stage Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>10<\/p>\n<\/td>\n<td>\n<p>Dry Eye Disease Therapeutics Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>11<\/p>\n<\/td>\n<td>\n<p>Dry Eye Disease Inactive Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>12<\/p>\n<\/td>\n<td>\n<p>Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>13<\/p>\n<\/td>\n<td>\n<p>Dry Eye Disease Key Companies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>14<\/p>\n<\/td>\n<td>\n<p>Dry Eye Disease Key Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>15<\/p>\n<\/td>\n<td>\n<p>Dry Eye Disease Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>16&nbsp;<\/p>\n<\/td>\n<td>\n<p>Dry Eye Disease Market Drivers and Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>17<\/p>\n<\/td>\n<td>\n<p>Dry Eye Disease Future Perspectives and Conclusion<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>18<\/p>\n<\/td>\n<td>\n<p>Dry Eye Disease Analyst Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>19<\/p>\n<\/td>\n<td>\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>20<\/p>\n<\/td>\n<td>\n<p>About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\"><strong><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF Report to know more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dry-eye-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Dry Eye Disease drugs and therapies<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=dry-eye-disease-pipeline-drugs-and-companies-insight-report-2023-updates-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +91 9568243403<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/r-and-d-analysis\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/r-and-d-analysis<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/r-and-d-analysis\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=dry-eye-disease-pipeline-drugs-and-companies-insight-report-2023-updates-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Las Vega (Nevada), United States \/\/\u2014 As per DelveInsight\u2019s assessment, globally, Dry Eye Disease pipeline constitutes key companies continuously working towards developing Dry Eye Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/dry-eye-disease-pipeline-drugs-and-companies-insight-report-2023-updates-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_639244.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-639244","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/639244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=639244"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/639244\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=639244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=639244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=639244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}